Journal of pharmacy & bioallied sciences · 2025
Safety and Efficacy of Oral Mifepristone for Cervical Ripening in Single Live Intrauterine Term Unscarred Pregnancies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rawat Sarika, Hedau Sheetal, Ahuja Avani, Mandloi Kirti, Rawat Sonu
Аннотация
BACKGROUND: Mifepristone results in cervical ripening in females undergoing pregnancy termination. It causes cervical ripening via blockage of progesterone receptors.
AIM: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies.
METHODS: The present study assessed 200 single live-term intrauterine unscarred pregnancies. All were induced using oral mifepristone in 400 mg dose after assessment of BS. A reassessment of BS was done after 24 hours and if needed (in BS < 6), 0.5 mg instilled dinoprostone was given intracervical in 1-3 doses at 6-hour intervals. In BS > 6, subjects were sent to the labor room for oxytocin infusion and ARM, if needed. BS gains after 24 hours, perinatal outcomes, delivery route, and induction to delivery interval were assessed.
RESULTS: The mean birth weight in study subjects was 2862.5 ± 85.2 grams. delivery mode was cesarean, outlet forceps delivery, ventouse delivery, and normal delivery in 8.5% (n = 17), 1.55% (n = 3), 3% (n = 6), and 87% (n = 174) study subjects respectively. Asphyxia or need for admission to NICU was reported in 4% (n = 8) of study subjects. re was 0.5% (n = 1) perinatal death in the study. Mean APGAR scores at the 1st and 5th minute were 8 and 9 respectively.
CONCLUSIONS: Mifepristone is efficacious and safe for inducing labor and cervical ripening in subjects with full-term pregnancy.
AIM: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies.
METHODS: The present study assessed 200 single live-term intrauterine unscarred pregnancies. All were induced using oral mifepristone in 400 mg dose after assessment of BS. A reassessment of BS was done after 24 hours and if needed (in BS < 6), 0.5 mg instilled dinoprostone was given intracervical in 1-3 doses at 6-hour intervals. In BS > 6, subjects were sent to the labor room for oxytocin infusion and ARM, if needed. BS gains after 24 hours, perinatal outcomes, delivery route, and induction to delivery interval were assessed.
RESULTS: The mean birth weight in study subjects was 2862.5 ± 85.2 grams. delivery mode was cesarean, outlet forceps delivery, ventouse delivery, and normal delivery in 8.5% (n = 17), 1.55% (n = 3), 3% (n = 6), and 87% (n = 174) study subjects respectively. Asphyxia or need for admission to NICU was reported in 4% (n = 8) of study subjects. re was 0.5% (n = 1) perinatal death in the study. Mean APGAR scores at the 1st and 5th minute were 8 and 9 respectively.
CONCLUSIONS: Mifepristone is efficacious and safe for inducing labor and cervical ripening in subjects with full-term pregnancy.